Results 121 to 130 of about 63,127 (238)

Optimal Stenting Strategy During Chemotherapy: Impact of Time to First Reintervention on Survival in Malignant Hilar Biliary Obstruction

open access: yesDEN Open, Volume 7, Issue 1, April 2027.
ABSTRACT Objectives Advances in chemotherapy have increased survival in biliary tract cancer patients, and reports of the effectiveness of neoadjuvant therapy are emerging. Accordingly, developing optimal drainage strategies under chemotherapy is important.
Katsuhiko Sato   +8 more
wiley   +1 more source

A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma

open access: yesAmerican Journal of Hematology, Volume 101, Issue 9, Page 2177-2189, September 2026.
ABSTRACT Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R‐Pola) in patients with relapsed/refractory (R/R) large B‐cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun‐Pola), with ...
Julio C. Chavez   +17 more
wiley   +1 more source

Transcriptome‐Based Classification of Resected Pancreatic Ductal Adenocarcinoma Enhances Prognostic Modelling Accuracy of Overall Survival Following Adjuvant Treatment

open access: yesInternational Journal of Cancer, Volume 159, Issue 5, Page 1322-1336, 1 September 2026.
Outcomes after resection of pancreatic ductal adenocarcinoma remain highly variable, and existing prognostic models lack sufficient accuracy. Here, the authors aimed to improve survival prediction by integrating transcriptome‐based subtyping into a validated clinical model and applying it to a multicenter real‐world cohort of fresh‐frozen resection ...
Marjolein F. Lansbergen   +20 more
wiley   +1 more source

Acidic bile salts induce APE1-dependent PRDX2 activation to drive oxaliplatin resistance via ferroptosis inhibition. [PDF]

open access: yesRedox Biol
Chen L   +13 more
europepmc   +1 more source

Nanomaterial‐Mediated Radiotherapy–Immunotherapy Combinations: Breaking Immunosuppression and Revolutionizing Cancer Treatment

open access: yesMedComm – Biomaterials and Applications, Volume 5, Issue 3, September 2026.
Nanomaterials integrate radiotherapy and immunotherapy by enhancing radiosensitivity, remodeling the immunosuppressive tumor microenvironment, and promoting systemic antitumor immunity. This review summarizes the latest strategies of nanomaterial‐mediated combinations (RT, immunotherapy, IRT) and highlights future directions for overcoming clinical ...
Peijie Li, Xiangqin Wang, Sisi He, Hu Ma
wiley   +1 more source

Chinese expert consensus on whole-process management of oxaliplatin-induced hypersensitivity reactions (2024 edition)

open access: yesZhongguo aizheng zazhi
Oxaliplatin serves as a basic therapeutic agent for various malignant tumors. Oxaliplatin-induced hypersensitivity reactions are potentially life-threatening, and frequently lead to treatment discontinuation.
中国抗癌协会肿瘤整体评估专业委员会   +1 more
doaj  

Oxidative and Antioxidant Systems in Ferroptosis of Cancer: Mechanisms, Regulations, and Therapeutic Targeting

open access: yesMedComm – Oncology, Volume 5, Issue 3, September 2026.
Ferroptosis is governed by the balance between reactive oxygen species (ROS)‐driven lipid peroxidation and a multi‐tiered antioxidant network. ROS sources include mitochondrial electron transport chain, voltage‐dependent anion channels, NADPH oxidases, and endoplasmic reticulum‐resident oxidoreductases, while antioxidant defenses span the primary GSH ...
Deepak K   +5 more
wiley   +1 more source

Nitric Oxide in Cancer: Mechanisms, Dual Role, and Therapeutic Strategies

open access: yesMedComm – Oncology, Volume 5, Issue 3, September 2026.
Nitric oxide exerts concentration‐dependent dual roles in cancer, functioning as either a tumor promoter or suppressor. This review comprehensively examines NO's multifaceted regulation of tumor biology, including S‐nitrosylation signaling, metabolic reprogramming, immunemodulation, and therapy resistance, and highlights emerging therapeutic strategies
Jia Shao   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy